期刊
CLINICAL IMMUNOLOGY
卷 176, 期 -, 页码 63-70出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2016.12.003
关键词
Doxorubicin; B cells; Immunology; Urinary bladder cancer; Neoadjuvant chemotherapy; CD86
类别
资金
- Swedish Cancer Foundation [4-837/2015]
- Wallenberg Foundation
- Swedish Medical Research Council
- Regionala forskningsradet i Uppsala-Orebroregionen (RFR in Uppsala-Orebro) [RFR-313841]
- Swedish Research Council [VLL-582631]
- Cancer Research Foundation in Norrland, Umed, Sweden [CFF LP 15-2073]
- Karolinska Research Network Program in Immune Modulatory Therapies for Autoimmunity and Cancer
Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4(+) T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-alpha. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy. (C) 2016 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据